官方服务：
资源简介：
Incremental cost-effectiveness ratios.
应用场景：
创建时间：
2016-12-31
相关数据集
Input parameters for the base-case analysis.
Background Expanding the indication of already approved immuno-oncology drugs presents treatment opportunities for patients but also strains healthcare systems. Cost-based pricing models are discussed
NIAID Data Ecosystem50
Using Penalized Synthetic Controls on Truncated data: A Case Study on Effect of Marijuana Legalization on Direct Payments to Physicians by Opioid Manufacturers
Amid increasing awareness regarding opioid addiction, medical marijuana has emerged as a substitute to opioids for pain management. Concurrently, opioid manufacturers are putting significant research
Taylor & Francis Group2024-11-19 更新40
DataSheet_2_Cost-Effectiveness Analysis of Influenza A (H1N1) Chemoprophylaxis in Brazil.pdf
Background: Oseltamivir and zanamivir are recommended for treating and preventing influenza A (H1N1) worldwide. In Brazil, this official recommendation lacks an economic evaluation. Our objective was
NIAID Data Ecosystem20
Costs and quality of life detriments associated with rotavirus vaccination at a coverage of 94.7% during 2015–2019 and without vaccination.
Costs and quality of life detriments associated with rotavirus vaccination at a coverage of 94.7% during 2015–2019 and without vaccination.
NIAID Data Ecosystem50
Results of scenario analyses for sCRT population.
Objective The effectiveness of sugemalimab vs. placebo in post-chemoradiotherapy patients with locally advanced, unresectable stage III NSCLC has been demonstrated and approved by China National Medic
NIAID Data Ecosystem20
